Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
JoAnn V Pinkerton, James Simon, Nick Panay, Christian Seitz, Susanne Parke, Cecilia Caetano, Uwe Mellinger, Nazanin Haseli Mashhadi, Claudia Haberland, Gordana Atanackovic, Cornelia Holz, Guangping Mao, Marina Morrison, Sven Nisius, Matthias Schaefers, Lineke Zuurman
{"title":"Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.","authors":"JoAnn V Pinkerton, James Simon, Nick Panay, Christian Seitz, Susanne Parke, Cecilia Caetano, Uwe Mellinger, Nazanin Haseli Mashhadi, Claudia Haberland, Gordana Atanackovic, Cornelia Holz, Guangping Mao, Marina Morrison, Sven Nisius, Matthias Schaefers, Lineke Zuurman","doi":"10.1097/gme.0000000000002350","DOIUrl":null,"url":null,"abstract":"Elinzanetant is a selective neurokinin-1,3 receptor antagonist in development for the treatment of vasomotor symptoms (VMS) associated with menopause. The pivotal, double-blind, randomized, placebo-controlled phase 3 studies Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms (OASIS) 1 and 2 will assess the efficacy and safety of elinzanetant in women with VMS.","PeriodicalId":18404,"journal":{"name":"Menopause","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Menopause","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/gme.0000000000002350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Elinzanetant is a selective neurokinin-1,3 receptor antagonist in development for the treatment of vasomotor symptoms (VMS) associated with menopause. The pivotal, double-blind, randomized, placebo-controlled phase 3 studies Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms (OASIS) 1 and 2 will assess the efficacy and safety of elinzanetant in women with VMS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
